Upcoming in March, AnaBios will be presenting and exhibiting at the 2017 Society of Toxicology Annual Meeting and Expo, taking place at the Baltimore Convention Center, March 13th – 16th. AnaBios’s exhibit/booth number is #519. Dr.’s Paul Miller and Najah Abi-Gerges will be in attendance to discuss the latest in research and service offerings. Poster presentations are as follows:
Tuesday, March 14th from 9:30 am to 12:45 pm: “Adult Human Primary Cardiomyocytes: An Integrative Translational Model for Cardiotoxicity Assessment.” Hall A of the Exhibit Hall area (Dr. Najah Abi-Gerges)
Thursday, March 16th from 8:30 am to 11:45 am: “A Human Ex-Vivo Contractility-Based Assay for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-Arrhythmia Risk.” Hall A of the Exhibit Hall (Dr. Najah Abi-Gerges).
If you will be at the meeting in March, please contact Alisen James: email@example.com, to let us know. We forward to connecting with both colleagues and clients.
AnaBios CEO Andre Ghetti has been invited to present at the 8th Japanese Safety Pharmacology Society Annual Meeting, taking place at the University of Tokyo, February 10th - 11th, 2017. Dr. Ghetti will speak on "Adult Human Ex-Vivo Cardiac Models for Preclinical Safety Assessment."
Dr. Najah Abi-Gerges, Scientific Director for AnaBios, has been accepted to speak at The Gordon Research Conference in February 2017, in Ventura, CA. Dr. Abi-Gerges will speak on "Proarrhythmia Predictions Using Primary Human Cardiomyocytes."
The Gordon Research Conference, founded in 1941, is a prestigious international scientific conference, dedicated to highlighting the latest in cutting-edge research in fields ranging from physics to neurobiology, and material science to medicine. The conference is limited to 200 attendees; all presenters must apply and be selected by conference chairs.
Purdue Pharma L.P. and AnaBios Corporation announced today a collaboration to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain. The goal of the collaboration is to accelerate Purdue's Nav1.7 sodium ion channel drug candidates utilizing AnaBios' Phase-X® discovery platform to develop treatments for chronic pain.
Under the terms of the agreement, Purdue Pharma will license to AnaBios the rights to a suite of patents for Nav1.7 sodium ion channel blockers. AnaBios will employ its Phase-X® technology to de-risk the assets and select a clinical candidate. The two companies will form a joint steering committee to manage pre-clinical as well as clinical development of the lead molecule. In addition, the companies will own any intellectual property (IP) developed jointly.
Purdue Pharma has more than 15 years of research history in the sodium channel field that led to multiple patent applications and numerous lead compounds targeting Nav1.7 as well as other sodium channel isoforms that are potentially useful for the treatment of chronic pain. Purdue Pharma also has extensive clinical development experience in advancing new drugs for treating pain.
AnaBios has a successful record of accomplishment in employing its Phase-X® platform to support target selection and validation, lead optimization, clinical candidate selection and clinical program de-risking for pharmaceutical drug development programs. The company is also conducting internal preclinical drug discovery programs on proprietary chemical entities and has established a unique and unprecedented capability for studying the human peripheral pain pathway in the laboratory, therefore enabling the identification of novel analgesic drugs with potential efficacy in humans.
“The Phase-X® platform enables the discovery of novel drugs directly in normal as well as diseased human tissues, minimizing animal experimentation. This strategy maximizes the chances that preclinical data will successfully translate during clinical development,” said Mark Timney, President and Chief Executive Officer, Purdue Pharma L.P. “This innovative technology can advance this important research and bring value to patients suffering from pain and healthcare providers.”
Phase-X® ensures that lead optimization truly enhances drug safety and efficacy profiles in humans, not just in animal models.
“We will utilize our Phase-X® technology to optimize the selection of clinical candidates from the advanced leads that Purdue Pharma has generated,” said Andre Ghetti, Ph.D., Chief Executive Officer, AnaBios Corporation. “Employing human sensory neurons to match the selectivity and properties of sodium channel blockers with specific pain indications, we will maximize the potential success of clinical development of much needed new pain therapeutics.”
“Through this unique collaboration we have a tremendous opportunity to quickly advance new treatments into the clinic and potentially serve the many chronic pain patients that cannot find relief with existing medications. Our ability to select clinical candidates based on experiments performed in native human tissues will provide the greatest chance of success,” said Don Kyle, Ph.D., Vice President, Discovery Research, Purdue Pharma L.P.
Purdue Pharma CEO, Mark Timney, discusses the company's strategy and the alliance with
AnaBios, in an interview with Pharma Intelligence's Mike Ward. An excerpt of the interview is
available by clicking on the video.
The findings of collaborative work between AnaBios, AbbVie, Novartis and Roche were presented at the 15th Annual Meeting of the Safety Pharmacology Society in Prague, Czech Republic. The presentation summarizes the results obtained employing Phase-X® ex-vivo human-based model that uses ventricular trabeculae from donor hearts, combined with sharp-electrode continuous recordings of the membrane potential to provide a novel approach for assessing pro-arrhythmic risks. The use of adult human cardiac tissue removes the potential for discrepancies in pharmacological sensitivity due to cross-species differences or immature cardiomyocyte phenotype. The study is part of a formal Biomarker Qualification project with the FDA.
Project aims to Advance Nav1.7 Sodium Ion Channel Drug Candidates with Phase-X® Discovery Platform
Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma's Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort would leverage Purdue Pharma's intellectual property and lead compounds, combined with AnaBios' Phase-X® technology.
Purdue Pharma has more than 10 years of research history in the sodium channel field that led to multiple patent applications and numerous lead compounds targeting Nav1.7 as well as other sodium channel isoforms that are potentially useful for the treatment of chronic pain. Purdue Pharma also has extensive clinical development experience in advancing new drugs for treating pain.
AnaBios is an innovative drug discovery company employing its proprietary Phase-X® technology to enable the discovery of novel drugs directly in human tissues, bypassing animal experimentation. AnaBios generates highly valuable and predictive human data that ensure the selection of the most effective and safest drugs before investing in expensive and time consuming clinical trials. AnaBios has established a unique and unprecedented capability for studying the human peripheral pain pathway in the laboratory, therefore enabling the identification of novel analgesic drugs with potential efficacy in humans.
"The prospect of combining AnaBios' unique platform and Purdue Pharma's top quality chemistry exemplifies the powerful nexus of technology-based discovery and industry collaboration," said Mark Timney, President and Chief Executive Officer, Purdue Pharma L.P. "This creative partnership fits in well with our strategic plan to continue development of our existing therapeutic programs and ultimately bring value to patients suffering from pain and to healthcare providers."
"We are very excited to have the opportunity to employ AnaBios' Phase-X® technology to optimize the selection of clinical candidates from the advanced leads that Purdue Pharma has generated," said Andre Ghetti, Ph.D, Chief Executive Officer, AnaBios Corporation. "Employing human sensory neurons to match the selectivity and properties of sodium channel blockers with specific pain indications, we will maximize the potential success of clinical development of much needed new pain therapeutics."
AnaBios presented results generated in collaboration with the Pain Center, of the Washington University School of Medicine, St Louis, MO. The data provide insight into how sodium and potassium channel conductances control excitability of human sensory neurons.
The findings of collaborative work between AnaBios, Lilly and Ironwood Pharmaceuticals were presented at the 15th World Congress on Pain in Buenos Aires, Argentina. In a first poster presentation, the effects of opioid drugs on human DRG neurons were reported, with specific emphasis on the modulation of sodium channels. A second presentation provided further mechanistic insight into how linaclotide, through guanylate cyclase-C agonism, reduces abdominal pain and improves constipation in patients with irritable bowel syndrome. AnaBios also presented data generated in collaboration with the Lawrence Livermore National Laboratory, demonstrating, for the first time, that gadolinium-based contrast agents can directly activate human nociceptive neurons, possibly explaining pain-related side effects reported in individual with compromised kidney function.
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase-X® technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
AnaBios will employ its unique and validated Phase-X® preclinical development platform which utilizes viable human tissues to generate human-relevant data at the pre-clinical stage. The use of Phase-X® technology advances lead optimization, clinical candidate selection and de-risking at the pre-clinical stage of development, significantly reducing the chances of failure during clinical testing, thus bringing new therapeutics to market more quickly at substantially lower cost."
"We are extremely excited about the acquisition of Zalicus' Nav1.7 pain portfolio and the opportunity that this brings to develop much needed non-addictive analgesics. By merging the sophisticated medicinal chemistry work products of Zalicus with the innovative AnaBios' Phase-X® technology, we have a great opportunity to quickly advance into the clinic new safe and effective drugs for the many patients that cannot find pain relief with existing medications. We feel that our ability to select clinical candidates based on human responses will provide the greatest chance of success," stated Andre Ghetti, Ph.D., CEO of AnaBios.
"AnaBios, with its proprietary Phase-X® technology platform supporting candidate selection and clinical development, is an ideal partner to advance these novel, oral, selective, state-dependent sodium channel blockers which represent a promising target for chronic pain," said Mark H.N. Corrigan, M.D., President and Chief Executive Officer of Zalicus.
AnaBios’ recently developed human heart-based drug safety evaluation platform will be utilized to test human cardiac responses to novel drug, providing the next best kin to a human clinical cardiac study, but avoiding the risks related to drug exposure in man, and the high costs and extended timelines which come with the clinical studies. The grant will support efforts focused on the optimization and validation of the ex-vivo heart platform in order to demonstrate its feasibility, robustness, and overall value in predicting human clinical responses.
The findings of a collaboration between the Royal Adelaide Hospital, University of Adelaide, Ironwood Pharmaceuticals Inc, and AnaBios, were presented at Digestive Disease Week Meeting, in Chicago. The results of the study provide further mechanistic insight into how linaclotide, through guanylate cyclase-C agonism, reduces abdominal pain and improves constipation in patients with irritable bowel syndrome.
Dr. Jack Reynolds, Executive Chairman at AnaBios Corporation, discussed the challenges and opportunities for safety pharmacology for the pharmaceutical industry with special emphasis on the recent advances in translational sciences.
AnaBios presented on the pharmachological profiling of sodium channel blockers in human and rodent DRG neurons. The data was generated by a collaboration between Convergence Pharmaceuticals, AnaBios and the University College London.
AnaBios presented on the biophysical and pharmacological characterization of native human sodium channels Nav1.8 from isolated dorsal root ganglia (DRG). The data was obtained though a collaborative research effort between Pfizer (Neusentis) and AnaBios.